文献速递心力衰竭与心肌病心律失常

心力衰竭患者心脏再同步治疗加用除颤功能后的性别特异性结局

Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure.
PubMed 文献 · Heart · 2017-01-19

该多中心观察性队列纳入5307例无持续性室性心律失常史的缺血性或非缺血性扩张型心肌病心力衰竭患者,比较心脏再同步治疗除颤器(CRT-D,n=4037)与心脏再同步治疗起搏器(CRT-P,n=1270)的结局并按性别分层。倾向评分匹配后男女均未见生存优势,逆概率加权下男性见获益而女性未见,CRT-P较CRT-D的多余未校正死亡中男性7.4%与女性2.2%归因于心脏性猝死。作者结论认为加用除颤器可能仅在经过良好选择的男性患者中带来额外获益。

要点

  • 倾向评分匹配后CRT-D与CRT-P在男性和女性中均未见生存优势。
  • 逆概率加权下男性CRT-D见获益(HR 0.78),女性未见(HR 0.87)。
  • CRT-P较CRT-D的多余未校正死亡归因于心脏性猝死者男性7.4%、女性2.2%。

核心结论

  • 在具有心脏再同步治疗适应证的初级预防患者中,加用除颤器可能仅在经过良好选择的男性患者中带来额外获益。

研究设计与样本

  • 多中心观察性队列研究,纳入5307例连续患者,均有缺血性或非缺血性扩张型心肌病且无持续性室性心律失常史,接受CRT-D(n=4037)或CRT-P(n=1270)植入。
  • 采用倾向评分匹配与加权并结合死因数据分析,比较CRT-D与CRT-P的结局,并按性别分层。

主要发现

  • 中位随访34个月(四分位距22-60个月)后,倾向评分匹配后CRT-D与CRT-P在男性中未见生存优势(HR=0.95,95%CI 0.77至1.16,p=0.61),在女性中也未见(HR=1.30,95%CI 0.83至2.04,p=0.25)。
  • 逆概率加权下男性患者见CRT-D获益(HR 0.78,95%CI 0.65至0.94,p=0.012),女性未见(HR 0.87,95%CI 0.63至1.19,p=0.43)。
  • CRT-P较CRT-D的多余未校正死亡归因于心脏性猝死者男性为7.4%,女性为2.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Among primary prevention patients with heart failure receiving cardiac resynchronisation therapy (CRT), the impact of additional implantable cardioverter defibrillator (ICD) treatment on outcomes and its interaction with sex remains uncertain. We aim to assess whether the addition of the ICD functionality to CRT devices offers a more pronounced survival benefit in men compared with women, as previous research has suggested. METHODS: Observational multicentre cohort study of 5307 consecutive patients with ischaemic or non-ischaemic dilated cardiomyopathy and no history of sustained ventricular arrhythmias having CRT implantation with (cardiac resynchronisation therapy defibrillator (CRT-D), n=4037) or without (cardiac resynchronisation therapy pacemaker (CRT-P), n=1270) defibrillator functionality. Using propensity score (PS) matching and weighting and cause-of-death data, we assessed and compared the outcome of patients with CRT-D versus CRT-P. This analysis was stratified according to sex. RESULTS: After a median follow-up of 34 months (interquartile range 22-60 months) no survival advantage, of CRT-D versus CRT-P was observed in both men and women after PS matching (HR=0.95, 95% CI 0.77 to 1.16, p=0.61, and HR=1.30, 95% CI 0.83 to 2.04, p=0.25, respectively). With inverse-probability weighting, a benefit of CRT-D was seen in male patients (HR 0.78, 95% CI 0.65 to 0.94, p=0.012) but not in women (HR 0.87, 95% CI 0.63 to 1.19, p=0.43). The excess unadjusted mortality of patients with CRT-P compared with CRT-D was related to sudden cardiac death in 7.4% of cases in men but only 2.2% in women. CONCLUSIONS: In primary prevention patients with CRT indication, the addition of a defibrillator might convey additional benefit only in well-selected male patients.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Barra S, Providência R, Duehmke R, et al. Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. Heart. 2017. PMID: 28104669. doi:10.1136/heartjnl-2016-310677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。